All In Biotech

Drug Trial Radar · NCT07728695

Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

PAIN-GP: Project Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
Staci Gruber, Ph.D.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.

Conditions

  • Endometriosis
  • Adenomyosis
  • Chronic Pelvic Inflammatory Disease

Interventions

  • Custom-formulated, high-CBD study productDrug

    2 doses of the high-CBD study product will be used, compared to placebo.

  • PlaceboDrug

    Placebo study product.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Quantification of parent CBD and its primary metabolites, 7-COOH-CBD and 7-OH-CBD, as well as metabolite-to-parent drug exposure ratios (MPR)Time frame: Baseline, 7 days
  2. Inflammatory markersTime frame: Baseline, 7 days
  3. Circulating anandamide (AEA)Time frame: Baseline, 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • McLean Hospital

    Belmont, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.